Dr. Gary Dubin, is Senior Vice President and Head of the Global Medical Office in the Takeda Vaccine Business Unit (VBU) and leads the Medical Affairs and Policy and Pharmacovigilance functions for vaccines.

Dr Dubin joined Takeda in September of 2015 has more than 31 years of experience in vaccine research. Prior to joining Takeda, he spent 20 years at GlaxoSmithKline (GSK) Biologicals (now GSK Vaccines) where, since 2010 he held the role of Vice President and Head, Global Late Clinical Development. During his career at GSK, he led global teams responsible for the clinical development and licensure of a broad range of vaccines addressing important unmet medical needs, including seasonal influenza (Fluarix Quadravalent and FluLaval Quadravalent), pandemic influenza (Pandemrix and Aprepandrix), meningococcal meningitis (Menhibrix and Nimenrix); human papilloma virus (Cervarix), rotavirus (Rotarix), strep pneumonia (Synflorix and protein-based vaccine in phase II development), malaria (RTS,S vaccine; submitted for licensure), herpes zoster (phase III); measles/mumps/rubella (US development program, phase III); tuberculosis (phase II), and others. He also supported Medical Affairs activities for these development programs and served as a core member of all major medical governance committees at GSK, including their Vaccines Medical Governance Board and the Vaccines Safety Board.

Dr Dubin holds a medical degree from the University of Pennsylvania and completed his Adult Internal Medicine residence training at the University of Colorado. He completed a fellowship in Clinical Infectious Disease and a postdoctoral research fellowship in Molecular Virology at the University of Pennsylvania. Prior to joining GSK, Dr Dubin served as Assistant Professor of Medicine in the Infectious Disease Division at the University of Pennsylvania and currently serves as Adjunct Associate Professor of Medicine at the same institution. He holds numerous patents in the vaccine field and has co-authors more than 85 scientific publications.